These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12658024)

  • 1. Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.
    Peters H; Rückert M; Gaedeke J; Liefeldt L; Ketteler M; Sharma AM; Neumayer HH
    J Hypertens; 2003 Apr; 21(4):771-80. PubMed ID: 12658024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
    Peters H; Daig U; Martini S; Rückert M; Schäper F; Liefeldt L; Krämer S; Neumayer HH
    Kidney Int; 2003 Aug; 64(2):509-18. PubMed ID: 12846746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
    Peters H; Border WA; Noble NA
    Kidney Int; 2000 Apr; 57(4):1493-501. PubMed ID: 10760085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.
    Yu L; Border WA; Anderson I; McCourt M; Huang Y; Noble NA
    Kidney Int; 2004 Nov; 66(5):1774-84. PubMed ID: 15496148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
    Peters H; Border WA; Noble NA
    Kidney Int; 1998 Nov; 54(5):1570-80. PubMed ID: 9844133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis.
    Peters H; Eisenberg R; Daig U; Liefeldt L; Westenfeld R; Gaedeke J; Krämer S; Neumayer HH
    Kidney Int; 2004 Jun; 65(6):2238-48. PubMed ID: 15149337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
    Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis.
    Gaedeke J; Boehler T; Budde K; Neumayer HH; Peters H
    Nephrol Dial Transplant; 2005 Feb; 20(2):319-28. PubMed ID: 15673690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
    Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
    Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.
    Zhang J; Gu C; Noble NA; Border WA; Huang Y
    Am J Physiol Renal Physiol; 2011 Oct; 301(4):F723-32. PubMed ID: 21795644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
    Ciechanowicz A
    Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension.
    Ceron CS; Rizzi E; Guimarães DA; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2013 Dec; 65():47-56. PubMed ID: 23806385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
    Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
    Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis.
    Hartner A; Hilgers KF; Bitzer M; Veelken R; Schöcklmann HO
    J Mol Med (Berl); 2003 Jan; 81(1):32-42. PubMed ID: 12545247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats.
    Volpini RA; da Silva CG; Costa RS; Coimbra TM
    Diabetes Metab Res Rev; 2003; 19(1):43-51. PubMed ID: 12592643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
    Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
    Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
    Briasoulis A; Oliva R; Kalaitzidis R; Flynn C; Lazich I; Schlaffer C; Bakris G
    J Clin Hypertens (Greenwich); 2013 Jul; 15(7):473-9. PubMed ID: 23815535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis.
    Peters H; Border WA; Noble NA
    Kidney Int; 2000 Mar; 57(3):992-1001. PubMed ID: 10720952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.